# EDGAR Filing Document

**Accession Number:** 0001608126
**File Stem:** 0001608126-25-000004
**Filing Date:** 2025-8
**Character Count:** 8936
**Document Hash:** 49b4db125ca6cb97b4d682989b6e8593
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001608126-25-000004.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001608126-25-000004

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250821

**EFFECTIVENESS DATE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Finepoint Capital LP
- **CENTRAL INDEX KEY:** 0001608126

**ORGANIZATION NAME:**
- **EIN:** 462183973
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-16580
- **FILM NUMBER:** 251238692

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** 24TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 336-2200

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** 24TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001608126

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Finepoint Capital LP

**Address:** 500 BOYLSTON STREET, BOSTON, MA 02116

**Telephone number:** 6173362200

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-16580

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [ ] No

- [x] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                 | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                     | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| QXO, Inc.                      | 82846H405 | 05/12/2025     | Advisory vote to approve executive compensation.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      2.44682e+07 |                0 | FOR         | 24468160.000000                          | FOR                         |  |
| Prothena Corporation plc       | G72800108 | 05/13/2025     | To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting.                                                                                        | SECTION 14A SAY-ON-PAY VOTES | 640071           |                0 | FOR         | 640071.000000                            | FOR                         |  |
| Cytokinetics, Incorporated     | 23282W605 | 05/14/2025     | To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement.                                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 309948           |                0 | FOR         | 309948.000000                            | FOR                         |  |
| SpringWorks Therapeutics, Inc. | 85205L107 | 05/14/2025     | Non-binding advisory vote on executive compensation                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| MoonLake Immunotherapeutics    | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Sarepta Therapeutics, Inc.     | 803607100 | 06/05/2025     | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Relay Therapeutics, Inc.       | 75943R102 | 06/06/2025     | To consider and act upon an advisory vote on the compensation of our named executive officers;                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Avidity Biosciences, Inc.      | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and                  | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Solid Biosciences Inc.         | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Xencor, Inc.                   | 98401F105 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| EyePoint Pharmaceuticals, Inc. | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| EyePoint Pharmaceuticals, Inc. | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Arvinas, Inc.                  | 04335A105 | 06/25/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |
| Revolution Medicines, Inc.     | 76155X100 | 06/26/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). | SECTION 14A SAY-ON-PAY VOTES |      0           |                0 |  |  |  |  |

## N-PX: Signature Block

**Reporting Person:** Finepoint Capital LP

**By (Signature):** Stacy L. Vezina

**By (Printed Signature):** Stacy L. Vezina

**By (Title):** General Counsel

**Date:** 08/21/2025